• Jing Xu, Li'e Sun, Song Luo, Guoqing Zhu, Yilang Zhou, Mei Jiang, and Min Wang.
• Department of Oncology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China. Electronic address: xujing4040@126.com.
• Am. J. Med. Sci. 2022 Apr 1; 363 (4): 342-350.

BackgroundThe purpose of this study was to evaluate the efficacy and safety of recombinant human endostatin (rh-ES) combined with chemotherapy in advanced gastrointestinal tumors in China.MethodsA literature search was performed in PubMed, Medline, Springer, Elsevier Science Direct, Weipu, Wanfang, and China National Knowledge Infrastructure (CNKI), with the last report through September 2019. The included research was scored using a modified Jadad scale, and a meta-analysis was performed using RevMan 5.3 software.ResultsTwenty articles including 905 participants (experimental group [rh-ES combined with chemotherapy] 459; control group [chemotherapy alone] 446) were considered. The total effective rate for the experimental group in advanced gastrointestinal tumors was higher than that of the control group (P<0.05). No significant difference in adverse reactions was seen between the two groups (P>0.05).ConclusionsThe short-term efficacy of rh-ES combined with chemotherapy for advanced gastrointestinal tumors was better, with fewer adverse reactions.Copyright © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

15 keywords...

hide…